Gene therapy hope for rare nerve disease enters first human tests

NCT ID NCT07180355

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a gene therapy called SGT-212 for Friedreich's ataxia, a rare genetic disease that damages the nervous system. Ten adults with the condition will receive the therapy through an injection into the brain and a vein. The main goal is to see if it is safe and tolerable over about 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SGT-212 (a gene therapy using a harmless virus to deliver a working copy of the frataxin gene)
What this could lead to
If it works, this could point toward a treatment that slows or stops Friedreich's ataxia progression.
What could go wrong
This is a very early, first-in-human trial with only 10 people. It is designed mainly to check safety, not effectiveness. Gene therapies can have unexpected side effects, and it may not work at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRIEDREICH'S ATAXIA (FA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Children's Hospital of Philadelphia (CHOP)

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Email: •••••@•••••

    Contact

  • The University of California, Los Angeles (UCLA)

    NOT_YET_RECRUITING

    Los Angeles, California, 90095, United States

    Contact Email: •••••@•••••

    Contact